NLRP3 Inflammasome-Activated Microglia
Overview
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">NLRP3 Inflammasome-Activated Microglia</th>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Activated microglia</td>
</tr>
<tr>
<td class="label">Activation State</td>
<td>Pro-inflammatory (M1-like)</td>
</tr>
<tr>
<td class="label">Key Feature</td>
<td>NLRP3 inflammasome assembly</td>
</tr>
<tr>
<td class="label">Primary Output</td>
<td>IL-1β, IL-18 secretion</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Throughout CNS</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>AD, PD, MS, stroke, TBI</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">View in Atlas</a></td>
</tr>
</table>
NLRP3 inflammasome-activated microglia are [microglia](/cell-types/microglia) that have undergone activation of the NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome complex, a multi-protein signaling platform that drives potent inflammatory responses. When activated, these microglia produce and secrete mature forms of the pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18, which amplify neuroinflammation and can contribute to neuronal damage. NLRP3 inflammasome activation in microglia is implicated in virtually all major neurodegenerative and neuroinflammatory diseases, making it a central therapeutic target for neuroprotection.
The NLRP3 Inflammasome Complex
...NLRP3 Inflammasome-Activated Microglia
Overview
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">NLRP3 Inflammasome-Activated Microglia</th>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Activated microglia</td>
</tr>
<tr>
<td class="label">Activation State</td>
<td>Pro-inflammatory (M1-like)</td>
</tr>
<tr>
<td class="label">Key Feature</td>
<td>NLRP3 inflammasome assembly</td>
</tr>
<tr>
<td class="label">Primary Output</td>
<td>IL-1β, IL-18 secretion</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Throughout CNS</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>AD, PD, MS, stroke, TBI</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">View in Atlas</a></td>
</tr>
</table>
NLRP3 inflammasome-activated microglia are [microglia](/cell-types/microglia) that have undergone activation of the NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome complex, a multi-protein signaling platform that drives potent inflammatory responses. When activated, these microglia produce and secrete mature forms of the pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18, which amplify neuroinflammation and can contribute to neuronal damage. NLRP3 inflammasome activation in microglia is implicated in virtually all major neurodegenerative and neuroinflammatory diseases, making it a central therapeutic target for neuroprotection.
The NLRP3 Inflammasome Complex
Structure and Components
The NLRP3 inflammasome is a cytosolic multi-protein complex consisting of:
NLRP3 (sensor protein): Contains leucine-rich repeats (LRR) for ligand sensing, a central NACHT domain for oligomerization, and a pyrin domain (PYD) for protein-protein interactions
ASC (apoptosis-associated speck-like protein containing a CARD): Adaptor protein linking NLRP3 to caspase-1 via its PYD and CARD domains
Pro-caspase-1: Inactive zymogen that becomes activated upon recruitment to the complex
Optional components: NEK7 (NIMA-related kinase 7), which facilitates NLRP3 oligomerizationActivation Mechanism (Two-Signal Model)
NLRP3 inflammasome activation requires two distinct signals:
Signal 1 (Priming): NF-κB-mediated transcriptional upregulation
- Triggered by: TLR ligands (LPS), TNF-α, IL-1β
- Upregulates: NLRP3, pro-IL-1β, pro-IL-18 gene expression
- Primes: Post-translational modifications of NLRP3 (deubiquitination, phosphorylation)
Signal 2 (Activation): Assembly and caspase-1 activation
- Triggered by diverse stimuli (see below)
- Results in: NLRP3 oligomerization → ASC speck formation → caspase-1 activation
- Outcomes: Pro-IL-1β/pro-IL-18 cleavage to mature cytokines; gasdermin D cleavage leading to pyroptotic cell death
Activating Stimuli in Microglia
Multiple damage-associated molecular patterns (DAMPs) and pathological signals activate microglial NLRP3:
- ATP: Extracellular ATP via P2X7 receptors → K⁺ efflux
- Protein aggregates: Amyloid-β, α-synuclein, tau oligomers → phagocytosis and lysosomal damage
- Crystals: Cholesterol crystals, uric acid → lysosomal disruption
- Mitochondrial dysfunction: mtDNA, ROS release
- Potassium efflux: Various mechanisms leading to low intracellular K⁺
- Calcium influx: Excessive Ca²⁺ entry
- Metabolic stress: Glucose deprivation, hypoxia
Functional Consequences
Cytokine Production
Activated caspase-1 cleaves:
- Pro-IL-1β → mature IL-1β: Potent pro-inflammatory cytokine that promotes neuroinflammation, induces COX-2, and enhances BBB permeability
- Pro-IL-18 → mature IL-18: Promotes IFN-γ production and Th1 responses
These cytokines amplify the inflammatory cascade by:
- Activating neighboring microglia and astrocytes
- Recruiting peripheral immune cells
- Inducing chemokine and adhesion molecule expression
- Impairing neuronal function and survival
Pyroptosis
Caspase-1 cleaves gasdermin D, forming pores in the plasma membrane that:
- Release IL-1β and IL-18 (lacking secretory signals)
- Cause lytic cell death (pyroptosis)
- Release DAMPs (ATP, HMGB1) that further activate neighboring cells
Pyroptotic microglial death perpetuates neuroinflammation through release of intracellular contents.
Altered Microglial Function
NLRP3-activated microglia exhibit:
- Enhanced phagocytosis (initially)
- Impaired debris clearance (chronically)
- Reduced neuroprotective functions
- Loss of homeostatic surveillance
- Secretion of neurotoxic factors (ROS, nitric oxide, glutamate)
Role in Neurological Disease
Alzheimer's Disease
In [Alzheimer's disease](/diseases/alzheimers-disease):
- Amyloid-β oligomers and fibrils activate microglial NLRP3
- IL-1β promotes tau hyperphosphorylation and cognitive decline
- Chronic activation impairs Aβ clearance, creating a vicious cycle
- ASC specks released from pyroptotic microglia seed amyloid pathology
- NLRP3 knockout reduces pathology in AD mouse models
NLRP3 inhibition is a leading therapeutic strategy for AD.
Parkinson's Disease
In [Parkinson's disease](/diseases/parkinsons-disease):
- α-synuclein aggregates potently activate NLRP3
- Dopaminergic neuron loss accelerated by IL-1β toxicity
- Neuroinflammation in substantia nigra driven by microglial NLRP3
- Genetic variants in NLRP3 associated with PD risk
- NLRP3 inhibition protects dopaminergic neurons in PD models
Multiple Sclerosis
In [multiple sclerosis](/diseases/multiple-sclerosis):
- NLRP3 activation contributes to demyelination
- IL-1β and IL-18 promote Th17 differentiation (pathogenic T cells)
- CNS inflammation perpetuated by microglial NLRP3
- EAE models show reduced severity with NLRP3 inhibition
Stroke and Traumatic Brain Injury
Following acute CNS injury:
- Massive ATP release and K⁺ fluctuations activate NLRP3
- Acute inflammation expands lesion size
- Chronic activation impairs functional recovery
- Therapeutic window: NLRP3 inhibition most effective if administered early
Aging
In normal aging:
- Chronic low-level NLRP3 activation contributes to "inflammaging"
- Accumulation of damage signals (oxidized lipids, dysfunctional mitochondria)
- Cognitive decline associated with elevated microglial IL-1β
- Senescent cells activate NLRP3 in surrounding microglia
Therapeutic Targeting
Small Molecule NLRP3 Inhibitors
Several selective inhibitors are in development:
- MCC950 (CP-456,773): First-generation specific NLRP3 inhibitor; highly effective in preclinical models but development halted due to hepatotoxicity
- OLT1177 (Dapansutrile): Oral NLRP3 inhibitor; clinical trials for heart disease and gout; potential CNS applications
- CY-09: Directly binds NLRP3 ATPase domain
- Tranilast: Repurposed anti-allergic drug; NLRP3 inhibitor with good safety profile
- Oridonin: Natural compound; covalently modifies NLRP3 cysteine residues
IL-1β Blocking Therapies
Targeting downstream products:
- Anakinra: IL-1 receptor antagonist (approved drug; poor BBB penetration)
- Canakinumab: Anti-IL-1β monoclonal antibody
- Both show efficacy in systemic inflammatory diseases; CNS applications limited by poor brain penetration
Caspase-1 Inhibitors
- VX-765 (Belnacasan): Prodrug inhibitor; CNS-penetrant; tested in epilepsy trials
- Broad effects beyond NLRP3 (inhibits all inflammasome-dependent caspase-1 activation)
Upstream Modulators
Targeting activation signals:
- P2X7 receptor antagonists: Block ATP-induced activation
- ROS scavengers: Reduce oxidative stress triggering
- Mitochondrial stabilizers: Prevent mtDNA/ROS release
- Lysosomal stabilizers: Reduce cathepsin B release
Cellular Therapies
- Microglial replacement: Transplanting non-activated microglia
- Engineered microglia: CRISPR-modified to lack NLRP3
- Exosome therapies: Delivering anti-inflammatory signals
Biomarkers and Detection
Identifying NLRP3-activated microglia:
- CSF IL-1β/IL-18 levels: Elevated in neuroinflammatory conditions
- PET imaging: TSPO ligands (general microglial activation); NLRP3-specific tracers in development
- Blood biomarkers: Circulating IL-1β, ASC specks
- Immunohistochemistry: ASC speck formation in tissue (post-mortem or biopsy)
Techniques for studying NLRP3-activated microglia:
- NLRP3-deficient mice: Genetic models revealing NLRP3 contributions
- ASC-Citrine mice: Visualize ASC speck formation in real-time
- Pharmacological inhibitors: Acute manipulations in vitro and in vivo
- Primary microglial cultures: Mechanistic studies with defined stimuli
- BV2/N9 cell lines: High-throughput screening platforms
- [Microglia](/cell-types/microglia) - Parent cell type
- [Neuroinflammation](/mechanisms/neuroinflammation) - Process driven by NLRP3 activation
- [IL-1β](/proteins/il1b) - Major cytokine product
- [Alzheimer's Disease](/diseases/alzheimers-disease) - Disease with prominent NLRP3 activation
- [Parkinson's Disease](/diseases/parkinsons-disease) - PD pathology involving NLRP3
- [Pyroptosis](/mechanisms/pyroptosis) - Cell death mechanism triggered by inflammasomes
- [Astrocytes](/cell-types/astrocytes) - Respond to microglial IL-1β
References
Heneka MT, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493(7434):674-678.
Venegas C, et al. Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer's disease. Nature. 2017;552(7685):355-361.
Gordon R, et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med. 2018;10(465):eaah4066.
Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477-489.
Coll RC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248-255.External Links
- [UniProt: NLRP3](https://www.uniprot.org/uniprot/Q96P20)
- [Inflammasome Database](http://www.inflammasomedb.com/)
- [PubMed: NLRP3 neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=NLRP3+inflammasome+neurodegeneration)
- [NCBI Gene: NLRP3](https://www.ncbi.nlm.nih.gov/gene/114548)